ClinicalTrials.gg

Mesothelioma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 305 studies for Mesothelioma across more than 10 countries. 59 are recruiting or about to start. 110 of them are mainly about Mesothelioma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Mesothelioma, Malignant too: 585 studies, 110 open.

Status

Completed
126
Terminated
59
Recruiting
46
Active, not recruiting
23
Status unknown
21
Withdrawn
12

Phase

Phase 1
131
Phase 2
126
Phase 3
16
Early Phase 1
6
Phase 4
4

Where

United States
188
United Kingdom
36
France
29
Italy
28
Canada
25
Spain
22

Who develops what

Add Mesothelioma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06097728 · AstraZeneca · Phase 3 · live · background · “Carboplatin” · registered Oct 2023
  • NCT05579366 · Genmab · Phase 2 · live · background · “Carboplatin” · registered Oct 2022
  • NCT04665206 · Vivace Therapeutics, Inc · Phase 2 · live · background · “Pemetrexed/Carboplatin” · registered Dec 2020
  • NCT02899299 · Bristol-Myers Squibb · Phase 3 · comparator · “Carboplatin” · registered Aug 2016
Eli Lilly and Company16% of its industry studies22 studies
pembrolizumabRecent, repeated
Evidence
  • NCT05732831 · Tango Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jan 2023
  • NCT05579366 · Genmab · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2022
  • NCT05070247 · Takeda · Phase 2 · background · “Pembrolizumab” · registered Sep 2021
  • NCT03277352 · Incyte Corporation · Phase 2 · background · “Pembrolizumab” · registered Aug 2017
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07510815 · Beijing Biotech · Phase 2 · live · background · “Cyclophosphamide” · registered Mar 2026
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
  • NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “cyclophosphamide” · registered Apr 2019
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07510815 · Beijing Biotech · Phase 2 · live · background · “Fludarabine” · registered Mar 2026
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Fludarabine” · registered Jun 2022
  • NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “fludarabine” · registered Apr 2019
Beijing Biotech18% of its industry studies22 studies

11 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
TEAD Inhibitor VT3989☆ Track1 live phase-3 study: NCT07824986Vivace Therapeutics, Inc

The 1 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 14 Mar 2027 est.EB-MF-CAR-NK-01 · Beijing Biotech · Phase 2 named, not the main aimstudied with Cyclophosphamidestudied with fludarabineNCT07510815 Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma — primary endpoint: Incidence of dose-limiting toxicities (DLTs) after first CAR-NK infusion · 36 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Mesothelioma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 3 open · Antimetabolites 2 open · Tyrosine kinase inhibitors (TKIs) 1 open · PARP inhibitors 1 open · Angiogenesis inhibitors 7

Coming up

23studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 46 Mesothelioma studies recruiting now, 31 (67%) set no upper age limit and 4 (9%) stop at 75 or younger. 7 (15%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (9%) take healthy volunteers.

Recruiting studies that take each age, of 46
AgeWomenMen
106 (13%)6 (13%)
1843 (93%)43 (93%)
3044 (96%)44 (96%)
4044 (96%)44 (96%)
5044 (96%)44 (96%)
6544 (96%)44 (96%)
7544 (96%)44 (96%)
8541 (89%)41 (89%)

Across all 305 studies, recruiting or not: 6% stop at 75 or younger and 1% at 65; 7% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Mesothelioma studies take

Of 42 phase 1 interventional studies under Mesothelioma, half reached primary completion within 45 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 145 mo29–63 · 42 studies——
Phase 243 mo25–67 · 36 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 305. Browse all 305 → or search them.